Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02749227 · OUTCOME

Change in Plasma Proopiomelanocortin (POMC) Levels

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors · Source last updated 2021-04-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Baseline, 12 months

What was measured

This is to measure the effect of Pasireotide LAR (long-acting release) treatment.

Analysis population: The study was terminated due to poor enrollment. The data was not collected or analyzed.

Groups in this outcome

Pasireotide LAR Therapy

Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed. Pasireotide LAR: Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use. The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pasireotide LAR Therapy0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
This is to measure the effect of Pasireotide LAR (long-acting release) treatment.
groups
  1. description
    Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed. Pasireotide LAR: Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use. The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.
    id
    OG000
    title
    Pasireotide LAR Therapy
population Description
The study was terminated due to poor enrollment. The data was not collected or analyzed.
reporting Status
POSTED
time Frame
Baseline, 12 months
title
Change in Plasma Proopiomelanocortin (POMC) Levels
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice